Insider Selling: Whitehawk Therapeutics (NASDAQ:WHWK) CEO Sells 102,395 Shares of Stock

by · The Cerbat Gem

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK – Get Free Report) CEO David James Lennon sold 102,395 shares of Whitehawk Therapeutics stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $3.51, for a total transaction of $359,406.45. Following the sale, the chief executive officer owned 691,154 shares of the company’s stock, valued at approximately $2,425,950.54. The trade was a 12.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David James Lennon also recently made the following trade(s):

  • On Wednesday, April 8th, David James Lennon sold 63,945 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.40, for a total transaction of $217,413.00.
  • On Tuesday, April 7th, David James Lennon sold 94,087 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.43, for a total transaction of $322,718.41.
  • On Thursday, April 2nd, David James Lennon sold 26,858 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.48, for a total transaction of $93,465.84.
  • On Monday, March 2nd, David James Lennon sold 5,100 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.31, for a total transaction of $16,881.00.

Whitehawk Therapeutics Trading Down 0.6%

NASDAQ WHWK traded down $0.02 on Wednesday, hitting $3.41. 212,634 shares of the company’s stock traded hands, compared to its average volume of 201,638. Whitehawk Therapeutics, Inc. has a 1-year low of $1.39 and a 1-year high of $4.48. The firm’s 50-day moving average price is $3.32 and its two-hundred day moving average price is $2.69. The firm has a market capitalization of $160.95 million, a PE ratio of 7.26 and a beta of 0.57.

Whitehawk Therapeutics (NASDAQ:WHWK – Get Free Report) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.21.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Oppenheimer assumed coverage on shares of Whitehawk Therapeutics in a research note on Thursday, February 5th. They issued an “outperform” rating and a $6.00 target price for the company. JonesTrading assumed coverage on shares of Whitehawk Therapeutics in a research note on Monday, December 22nd. They issued a “buy” rating and a $7.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research note on Friday, March 27th. Finally, Wall Street Zen upgraded shares of Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Whitehawk Therapeutics presently has an average rating of “Hold” and an average target price of $6.50.

Check Out Our Latest Analysis on Whitehawk Therapeutics

Hedge Funds Weigh In On Whitehawk Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. KVP Capital Advisors LP acquired a new position in Whitehawk Therapeutics during the fourth quarter worth $5,242,000. Quadrature Capital Ltd acquired a new position in Whitehawk Therapeutics during the fourth quarter worth $28,000. Eversept Partners LP acquired a new position in Whitehawk Therapeutics during the fourth quarter worth $630,000. ADAR1 Capital Management LLC acquired a new position in Whitehawk Therapeutics during the fourth quarter worth $188,000. Finally, Marshall Wace LLP acquired a new position in Whitehawk Therapeutics during the fourth quarter worth $164,000. 52.08% of the stock is currently owned by institutional investors and hedge funds.

About Whitehawk Therapeutics

(Get Free Report)

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

See Also